Targeting of Tumor Cells by Cell Surface Urokinase Plasminogen Activator-dependent Anthrax Toxin
Overview
Authors
Affiliations
Urokinase plasminogen activator receptor (uPAR) binds pro-urokinase plasminogen activator (pro-uPA) and thereby localizes it near plasminogen, causing the generation of active uPA and plasmin on the cell surface. uPAR and uPA are overexpressed in a variety of human tumors and tumor cell lines, and expression of uPAR and uPA is highly correlated to tumor invasion and metastasis. To exploit these characteristics in the design of tumor cell-selective cytotoxins, we constructed mutated anthrax toxin-protective antigen (PrAg) proteins in which the furin cleavage site is replaced by sequences cleaved specifically by uPA. These uPA-targeted PrAg proteins were activated selectively on the surface of uPAR-expressing tumor cells in the presence of pro-uPA and plasminogen. The activated PrAg proteins caused internalization of a recombinant cytotoxin, FP59, consisting of anthrax toxin lethal factor residues 1-254 fused to the ADP-ribosylation domain of Pseudomonas exotoxin A, thereby killing the uPAR-expressing tumor cells. The activation and cytotoxicity of these uPA-targeted PrAg proteins were strictly dependent on the integrity of the tumor cell surface-associated plasminogen activation system. We also constructed a mutated PrAg protein that selectively killed tissue plasminogen activator-expressing cells. These mutated PrAg proteins may be useful as new therapeutic agents for cancer treatment.
Anthrax: Transmission, Pathogenesis, Prevention and Treatment.
Sangwan N, Gangwal A, Jain P, Langtso C, Srivastava S, Dhawan U Toxins (Basel). 2025; 17(2).
PMID: 39998073 PMC: 11860322. DOI: 10.3390/toxins17020056.
Anthrax lethal toxin exerts potent metabolic inhibition of the cardiovascular system.
Liu J, Zuo Z, Fattah R, Finkel T, Leppla S, Liu S mBio. 2024; 15(12):e0216024.
PMID: 39508614 PMC: 11633152. DOI: 10.1128/mbio.02160-24.
Targeting canine mammary neoplastic epithelial cells with a reengineered anthrax toxin: first study.
da Fonseca I, Nagamine M, Gentile L, Nishiya A, da Fonseca J, de Oliveira Massoco C Vet Res Commun. 2024; 48(4):2407-2428.
PMID: 38805149 DOI: 10.1007/s11259-024-10400-5.
Cancer Drug Delivery Systems Using Bacterial Toxin Translocation Mechanisms.
Yin L, Thaker H Bioengineering (Basel). 2023; 10(7).
PMID: 37508840 PMC: 10376142. DOI: 10.3390/bioengineering10070813.
AB Toxins as High-Affinity Ligands for Cell Targeting in Cancer Therapy.
Marquez-Lopez A, Fanarraga M Int J Mol Sci. 2023; 24(13).
PMID: 37446406 PMC: 10343017. DOI: 10.3390/ijms241311227.